Sun Pharmaceutical Industries Ltd, for the second quarter ended September 30, 2025 reported a 2.6% growth in consolidated net profit to ₹3,118 crore.
Consolidated sales income for the quarter grew 8.6% Year on Year (YoY) to ₹14,405 crore.
Kirti Ganorkar, Managing Director, said, “India, Emerging Markets and Rest of World led our growth for the period. U.S. sales of innovative medicines have surpassed generics for the first time during the quarter.”
“We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability,” he added
Formulation sales in India were ₹4,735 crore up 11%. India formulation sales accounted for 32.9% of the total consolidated sales for the quarter.
Sun Pharma’s market share increased from 8% to 8.3%.
Formulation sales in the U.S. stood at $496 million, registering a decline of 4.1%. The decline in generics business was offset by growth in innovative medicines. U.S. sales accounted for approximately 30.1% of the total consolidated sales, the company said.
Emerging Markets formulations sales were $325 million for Q2FY26, up by 10.9% and accounted for 19.7% of total consolidated sales.
Formulation sales in rest of world (RoW) markets were $234 million for the quarter, up by 17.7% and accounted for 14.2% of the total consolidated sales for the quarter.